Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Z0AM
|
||||
| Former ID |
DNCL001780
|
||||
| Drug Name |
PSI-697
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Atherosclerosis; Thrombosis [ICD9: 414.0, 440, 437.6, 453, 671.5, 671.9; ICD10:I70, I80-I82] | Phase 1 | [1] | ||
| Company |
Pfizer
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H18ClNO3
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | P-selectin | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | ||||
| Malaria | |||||
| Staphylococcus aureus infection | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| amb2 Integrin signaling | |||||
| Reactome | Platelet degranulation | ||||
| Cell surface interactions at the vascular wall | |||||
| WikiPathways | Human Complement System | ||||
| Spinal Cord Injury | |||||
| Cell surface interactions at the vascular wall | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00367692) Study Evaluating PSI-697 in Patients With Scleritis. U.S. National Institutes of Health. | ||||
| REF 2 | Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.